CapsoVision, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $301.3M
- Price
- $6.02
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.86%
- Volume
- 68.7K
About
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Quick stats
Shares outstanding50.0M
Computed float34.0M
Float / shares68.0%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001378325
Websitehttps://capsovision.com
AI Summary
AI-generated1/12
minormixedearnings
CapsoVision Reports Second Quarter 2026 Financial Results
CapsoVision reported Q2 2026 revenue of $3.6 million, up 10% year-over-year, driven by increased capsule volume despite a 3% decline in average selling price.
Gross margin fell to 51% from 55% due to competitive pricing and tariffs, while operating expenses rose 46% to $9.5 million, resulting in a net loss of $7.5 million.
The company launched its AI Highlights feature in the EU and anticipates FDA clearance by Q3, while securing a $100 million at-the-market equity offering facility and appointing Dr. David S. Shields to the board.
Red flags
- Gross margin declined to 51% from 55% due to tariffs and competitive pricing pressure
- Operating expenses increased by $3.0 million year-over-year, widening net loss
- Cash balance of $9.1 million is low relative to the $14.5 million six-month burn rate